AssetMark Inc
TAK icon

AssetMark Inc’s Takeda Pharmaceutical TAK Stock Holding History

AssetMark Inc’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.04M Buy
314,687
+87,071
+38% +$1.44M 0.01% 727
2026
Q1 		$4.22M Buy
227,616
+71,496
+46% +$1.25M 0.01% 710
2025
Q4 		$2.43M Buy
156,120
+33,902
+28% +$485K 0.01% 811
2025
Q3 		$1.79M Buy
122,218
+26,498
+28% +$394K ﹤0.01% 843
2025
Q2 		$1.48M Buy
95,720
+9,181
+11% +$136K ﹤0.01% 839
2025
Q1 		$1.29M Buy
86,539
+372
+0.4% +$5.21K ﹤0.01% 820
2024
Q4 		$1.14M Buy
86,167
+5,185
+6% +$71.2K ﹤0.01% 823
2024
Q3 		$1.15M Buy
80,982
+4,500
+6% +$63.8K ﹤0.01% 764
2024
Q2 		$990K Buy
76,482
+890
+1% +$11.8K ﹤0.01% 769
2024
Q1 		$1.05M Buy
75,592
+3,864
+5% +$56.2K ﹤0.01% 721
2023
Q4 		$1.02M Buy
71,728
+193
+0.3% +$2.74K ﹤0.01% 669
2023
Q3 		$1.11M Buy
71,535
+1
+0% +$15 ﹤0.01% 598
2023
Q2 		$1.12M Buy
71,534
+4,946
+7% +$81K ﹤0.01% 590
2023
Q1 		$1.1M Buy
66,588
+51,648
+346% +$823K ﹤0.01% 587
2022
Q4 		$233K Buy
14,940
+1,090
+8% +$15.2K ﹤0.01% 798
2022
Q3 		$180K Buy
13,850
+988
+8% +$13.7K ﹤0.01% 776
2022
Q2 		$181K Sell
12,862
-960
-7% -$13.7K ﹤0.01% 753
2022
Q1 		$198K Buy
13,822
+1,152
+9% +$16.9K ﹤0.01% 731
2021
Q4 		$173K Buy
12,670
+667
+6% +$9.36K ﹤0.01% 728
2021
Q3 		$197K Buy
+12,003
New +$202K ﹤0.01% 570
2021
Q1 		– Sell
-62,049
Closed -$1.13M – 1523
2020
Q4 		$1.13M Buy
62,049
+24,680
+66% +$433K 0.01% 343
2020
Q3 		$667K Buy
37,369
+9,134
+32% +$166K ﹤0.01% 375
2020
Q2 		$506K Buy
28,235
+8,843
+46% +$159K ﹤0.01% 384
2020
Q1 		$294K Sell
19,392
-70,986
-79% -$1.29M ﹤0.01% 431
2019
Q4 		$1.78M Buy
90,378
+43,104
+91% +$825K 0.01% 317
2019
Q3 		$813K Buy
47,274
+39,829
+535% +$689K 0.01% 331
2019
Q2 		$132K Buy
7,445
+6,075
+443% +$111K ﹤0.01% 549
2019
Q1 		$28K Buy
+1,370
New +$27.6K ﹤0.01% 815

Other funds holding TAK

CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
EI
Ethic Inc New York $8.02B AUM 45.39% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $6.03B AUM 24.5% 1-Year Est. Return
LWAM
Legacy Wealth Asset Management Woodbury, Minnesota $456M AUM 35.19% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SCP
Sivia Capital Partners Mill Valley, California $822M AUM 48.82% 1-Year Est. Return
HCMT
Highland Capital Management (Tennessee) Memphis, Tennessee $2.17B AUM 54.74% 1-Year Est. Return

AssetMark Inc's TAK Position: Q2 2026 in Review

AssetMark Inc increased its Takeda Pharmaceutical (TAK) stake by 38% in Q2 2026, buying an estimated $1.44M and bringing the position to 314,687 shares worth $5.04M. The position accounts for 0.01% of the portfolio, ranked #727.

AssetMark Inc first reported a position in TAK in Q1 2019 and has held it in 28 quarters since. 124 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • AssetMark Inc held 314,687 shares of Takeda Pharmaceutical worth $5.04M as of Q2 2026.
  • AssetMark Inc bought 87,071 Takeda Pharmaceutical shares in Q2 2026, an estimated $1.44M.
  • Takeda Pharmaceutical made up 0.01% of AssetMark Inc's portfolio in Q2 2026, its #727 holding.
  • AssetMark Inc first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 28 quarters since.
  • 124 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.